This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279–286.
Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676–684.
Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101: 1637–1644.
Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D et al. Differentiation of naïve cord blood T cells into CD19-specific cytolytic effectors for post-transplant adoptive immunotherapy. Blood 2006; 107: 2643–2652.
Riddell SR, Greenberg PD . The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990; 128: 189–201.
Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20: 143–148.
Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005; 105: 1622–1631.
Rossig C, Bar A, Pscherer S, Altvater B, Pule M, Rooney CM et al. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors. J Immunother 2006; 29: 21–31.
Acknowledgements
We thank Lucy Brown, Claudia Spalla and Chy-Anh Tran for help with flow cytometry and cell sorting, Dr David Smith for help with statistical analyses and Dr Wichai Prayoonwiwat from Thailand for support and advice. This work was supported by, CA30206, CA003572, CA107399, Phramongkutklao Royal Thai Army Hospital and College of Medicine, The Alliance for Cancer Gene Therapy, The Amy Phillips Charitable Foundation, The Leukemia and Lymphoma Society, The Lymphoma Research Foundation, The National Foundation for Cancer Research, The Pediatric Cancer Research Foundation, The National Marrow Donor Program and The Marcus Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Numbenjapon, T., Serrano, L., Singh, H. et al. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 20, 1889–1892 (2006). https://doi.org/10.1038/sj.leu.2404329
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404329
This article is cited by
-
Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy
Gene Therapy (2018)
-
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor
Cancer Gene Therapy (2015)
-
Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor
Molecular Therapy (2013)
-
Adoptive cellular immunotherapy for childhood malignancies
Bone Marrow Transplantation (2008)
-
Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory Molecules
Molecular Therapy (2007)